Speaker 2: Sophia Frangou, USA

نویسندگان

  • Trevor Robbins
  • UK
  • Eduard Vieta
  • Spain
چکیده

s | 25 further mechanistic evidence for its beneficial effect on cognitive function. Through continued research efforts vortioxetine showed to be an antidepressant with a distinct clinical and pharmacological profile different from other currently available antidepressants, with a proven beneficial effect on CD in patients with MDD. Speaker 4: Trevor Robbins, UK Title: Translational models for drug discovery in depression Abstract Clinical depression entails cognitive deficits often across a range of domains including impairments, not only of memory but also executive functioning, such as decision-making, sustained attention (‘concentration’) and working memory, although these deficits are frequently age-dependent and correlated with discrete brain pathology. I will review evidence of heterogeneous and homologous patterns of cognitive deficit across a number of human and animal studies focusing especially on decision-making and attention, measured in a variety of ways. In addition, it is evident that depression is also associated with distinctive cognitive or affective biases evident in different settings, such as a tendency to say “no” in tests of memory recognition, to over-respond to faces expressing negative emotion, to overreact to negative feedback and also to respond more quickly to sad rather than happy words. These phenomena indicate the importance in depression of a motivational interface with respect to cognitive function and vice versa. By comparison, preclinical models of depression have frequently been criticised for their emphasis on species-typical maladaptive responses to stress (as in chronic mild stress, learned helplessness and ‘behavioural despair’), that are more predictive of the effects of drugs assumed to have anti-depressant effects than the symptoms of human depression themselves. Recently however, relevant aspects of behaviour such as affective bias and response to negative feedback have been employed successfully in rodents in a manner parallel to what is measured in human depressed patients, using for example tests of generalisation and probabilistic reversal learning. These new tests may complement the rich translational tests we already have available for assessing other aspects of cognition in humans and experimental animals and their neural correlates.Clinical depression entails cognitive deficits often across a range of domains including impairments, not only of memory but also executive functioning, such as decision-making, sustained attention (‘concentration’) and working memory, although these deficits are frequently age-dependent and correlated with discrete brain pathology. I will review evidence of heterogeneous and homologous patterns of cognitive deficit across a number of human and animal studies focusing especially on decision-making and attention, measured in a variety of ways. In addition, it is evident that depression is also associated with distinctive cognitive or affective biases evident in different settings, such as a tendency to say “no” in tests of memory recognition, to over-respond to faces expressing negative emotion, to overreact to negative feedback and also to respond more quickly to sad rather than happy words. These phenomena indicate the importance in depression of a motivational interface with respect to cognitive function and vice versa. By comparison, preclinical models of depression have frequently been criticised for their emphasis on species-typical maladaptive responses to stress (as in chronic mild stress, learned helplessness and ‘behavioural despair’), that are more predictive of the effects of drugs assumed to have anti-depressant effects than the symptoms of human depression themselves. Recently however, relevant aspects of behaviour such as affective bias and response to negative feedback have been employed successfully in rodents in a manner parallel to what is measured in human depressed patients, using for example tests of generalisation and probabilistic reversal learning. These new tests may complement the rich translational tests we already have available for assessing other aspects of cognition in humans and experimental animals and their neural correlates. S16: Cognitive Function in Bipolar Disorder: State of the Art Chair: Lakshmi Yatham, Canada Co-Chair: Shigenobu Kanba, Japan Speaker 1: Eduard Vieta, Spain Title: Cognitive impairment in bipolar disorder: Magnitude, moderators, and prevention strategies Abstract Neurocognition has been the focus of extensive research in schizophrenia and, more recently, in bipolar disorder and in depression (1). Neuropsychological testing may represent a tool able to identify potential neuroimaging markers and endophenotypes and to better understand the underlying neurophysiology (2). However, only lately the highly consistent findings from research began to be applied to clinical practice, and many clinicians are not yet much aware of how neurocognitive deficits affect their patients’ daily life, and, importantly, what can be done to prevent or at least mitigate cognitive impairment. Recent evidence suggests that neurocognitive status may be the most powerful predictor of functional outcome in BD, even more so than clinical features. Cognitive deficits may be related to neurodevelopmental issues, but in bipolar disorder the most accepted model is the “neuroprogression” one, in which recurring episodes and concurrent allostatic load contribute to neuropsychological difficulties and disability. Comorbidities and medication may also contribute to cognitive deficits. Research efforts are now focusing on drugs to ameliorate cognition and psychological interventions, such as functional remediation (3), which may have a positive impact on cognitive and functional outcome. Potential strategies aimed at preventing cognitive impairment and neuroprogression include: Effective pharmacotherapy for relapse prevention, psychoeducation, healthy habits (physical exercise, diet, sleep, no smoking), and cognitive enhancing psychological interventions (i.e.: promotion of cognitive reserve) and pro-cognitive drugs.Neurocognition has been the focus of extensive research in schizophrenia and, more recently, in bipolar disorder and in depression (1). Neuropsychological testing may represent a tool able to identify potential neuroimaging markers and endophenotypes and to better understand the underlying neurophysiology (2). However, only lately the highly consistent findings from research began to be applied to clinical practice, and many clinicians are not yet much aware of how neurocognitive deficits affect their patients’ daily life, and, importantly, what can be done to prevent or at least mitigate cognitive impairment. Recent evidence suggests that neurocognitive status may be the most powerful predictor of functional outcome in BD, even more so than clinical features. Cognitive deficits may be related to neurodevelopmental issues, but in bipolar disorder the most accepted model is the “neuroprogression” one, in which recurring episodes and concurrent allostatic load contribute to neuropsychological difficulties and disability. Comorbidities and medication may also contribute to cognitive deficits. Research efforts are now focusing on drugs to ameliorate cognition and psychological interventions, such as functional remediation (3), which may have a positive impact on cognitive and functional outcome. Potential strategies aimed at preventing cognitive impairment and neuroprogression include: Effective pharmacotherapy for relapse prevention, psychoeducation, healthy habits (physical exercise, diet, sleep, no smoking), and cognitive enhancing psychological interventions (i.e.: promotion of cognitive reserve) and pro-cognitive drugs.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Robotic therapy for chronic stroke : general recovery of impairment 4 or improved task - specific skill

1 2 3 Robotic therapy for chronic stroke: general recovery of impairment 4 or improved task-specific skill? 5 6 7 8 Authors: Tomoko Kitago, Jeff Goldsmith, Michelle Harran, Leslie Kane, Jessica Berard, 9 Sylvia Huang, Sophia L. Ryan, Pietro Mazzoni, John W. Krakauer, Vincent S. Huang 10 11 12 1 Department of Neurology, Columbia University College of Physicians and Surgeons, New York, 13 NY, USA...

متن کامل

Pathophysiology of early onset schizophrenia.

Early onset schizophrenia (with onset before adulthood) represents a rarer and possibly more severe form of the disorder which has received particular attention in the last two decades. Current evidence strongly suggest continuity with adult onset schizophrenia, with phenomenological, cognitive, genetic and neuroimaging data pointing towards similar neurobiological correlates and clinical defic...

متن کامل

Advancing the pharmacological treatment of bipolar depression

Bipolar disorder is a recurring, often chronic, illness characterised by periods of mania and depression with variable inter-episode recovery. For the majority of patients it is the depressive component of this illness that contributes to most of the associated morbidity, social disability and mortality. Research and clinical experience suggest that acute treatment and prevention of depressive ...

متن کامل

Bulking up the hippocampus in schizophrenia: a role for 5-HT1A agonists?

SUMMARY The volume of the hippocampus is reduced in patients with schizophrenia, and this deficit tends to become more pronounced with chronicity. Newer antipsychotics may protect against the progressive reductions in hippocampal volume while preliminary data offer hope that specific antipsychotics may act to reverse it. DECLARATION OF INTEREST None. COPYRIGHT AND USAGE © The Royal College ...

متن کامل

The prevalence of depression in bipolar disorder

Bipolar disorder is a recurring, often chronic, illness characterised by periods of mania and depression with variable inter-episode recovery. For the majority of patients it is the depressive component of this illness that contributes to most of the associated morbidity, social disability and mortality. Research and clinical experience suggest that acute treatment and prevention of depressive ...

متن کامل

A systems neuroscience perspective of schizophrenia and bipolar disorder.

Neuroimaging studies have generated a large body of knowledge regarding the neural correlates of schizophrenia (SZ) and bipolar disorder (BD). However, the initial goal of identifying disease-specific topographical mappings to localized brain regions or to distinct neural networks has not materialized and may be untenable. This contribution will argue that a systems neuroscience approach may pr...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 19  شماره 

صفحات  -

تاریخ انتشار 2016